)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Oncopeptides
Oncopeptides (ONCO) investor relations material
Oncopeptides Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Q3 net sales reached SEK 28.5m, up 41% YoY; 9M sales were SEK 84.9m, up 61%, and trailing-12-month sales exceeded SEK 100m.
Positive cash flow from European Pepaxti commercial operations remains targeted for 2027.
CHMP recommended third-line Pepaxti use; initial INSULA data showed blood-brain-barrier penetration in glioblastoma patients.
Financial highlights
Q3 net sales were SEK 28.5m vs SEK 20.2m; gross profit was SEK 28.0m vs SEK 19.9m.
Q3 operating loss was SEK 36.5m vs SEK 47.1m and net loss SEK 44.0m vs SEK 60.9m; 9M net loss was SEK 130.9m vs SEK 184.4m.
9M gross margin was 98%; reported operating expenses were SEK 64.5m in Q3 and SEK 205.9m for 9M.
Q3 operating cash outflow was SEK 37.7m vs SEK 33.7m; 9M outflow was SEK 126.1m vs SEK 156.4m.
Outlook and guidance
Positive cash flow from Pepaxti commercialization remains targeted for 2027; third-line expansion would support, but is not required for, the target.
European Commission decision on third-line expansion was expected in Q4 2026; a German access dossier was planned within ~1 month of approval, with Italy and Spain launch preparations underway.
FY 2026 operating costs were expected near the just-below-SEK 300m benchmark; Q4 sales were not formally forecast and expectations assumed no unexpected events.
Third-line use could double the addressable European patient population and treatment cycles, subject to approval.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Oncopeptides
- INSULA confirmed human blood-brain barrier penetration in three glioblastoma patients, with consistent safety.ONCO
Study update - Q2 2026 sales up 62% YoY, with strong margins and regulatory expansion underway.ONCOQ2 2026
- Validated PDC platform and rapid sales growth fuel global expansion and glioblastoma innovation.ONCOLife Science Conference 2026
- Rapid sales growth and pipeline innovation position for major expansion in oncology markets.ONCOAktiedagarna 2026
- 91% sales growth, strong margins, and major expansion plans supported by a SEK 200m rights issue.ONCOQ1 2026
- Validated PDC platform and glioblastoma program drive rapid growth and global expansion.ONCOStora Aktiedagarna 2026
- European Pepaxti growth and differentiated platforms support global expansion.ONCOCMD 2025
- Q2 2024 sales up 60%, SEK 8.2m revenue, and SEK 383m cash after rights issue.ONCOQ2 2024
- Q4 sales rose 35% in Europe, with regulatory wins and profitability targeted by 2026.ONCOQ4 2024
Next Oncopeptides earnings date
Q4 202618 Feb, 2027
Oncopeptides
Next Oncopeptides earnings date
Q4 202618 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Oncopeptides AB, a biotech company, focuses on the development of therapies for patients with cancer. The company's lead drug candidate is melflufen, which has received orphan drug designation from the European Commission, as well as from the FDA for the treatment of multiple myeloma. Its product pipeline also comprises peptide-drug conjugates that are in preclinical stage development for hematological malignancies and solid tumors. The company is based in Stockholm, Sweden